Claims

1. Use of an inhibitor of EGFR signalling and of MyD88-dependent TLR/IL-R1 signalling, in the manufacture of a medicament for the prevention or treatment of a neurodegenerative disease, wherein the inhibitor of EGFR signalling and of MyD88-dependent TLR/IL-R1 signalling is gefitinib and the disease is amyotrophic lateral sclerosis (ALS).

2. The use according to claim 1, wherein the EGFR inhibitor inhibits EGFR signalling so as to inhibit microglial cell activation and/or formation of inclusions of TDP43.

3. The use according to claim 1 or 2, wherein the EGFR inhibitor inhibits formation of inclusions of TDP43 by inducing deacetylation of TDP43.

4. The use according to any of claims 1 to 3, wherein the EGFR inhibitor inhibits EGFR signalling by inhibiting EGFR tyrosine kinase activity.

5. The use according to any of claims 1 to 4, wherein the inhibitor of EGFR signalling is an inhibitor of EGFR tyrosine kinase.

6. The use according to any of claims 1 to 5, wherein the inhibitor of MyD88-dependent TLR/IL-R1 signalling inhibits MyD88-dependent TLR/IL-R1 signalling so as to inhibit production of IL-1β and NFkB and/or to inhibit formation of inclusions of TDP43.

7. The use according to claim 6, wherein the inhibitor of MyD88-dependent TLR/IL-R1 signalling inhibits formation of inclusions of TDP43 by inhibiting phosphorylation of TDP43.

8. The use according to any of claims 1 to 7, wherein the inhibitor of MyD88-dependent TLR/IL-R1 signalling inhibits MyD88-dependent TLR/IL-R1 signalling by inhibiting IRAK1 and/or IRAK4.

9. The use according to any of claims 1 to 8, wherein the inhibitor of EGFR signalling, and the inhibitor of MyD88-dependent TLR/IL-R1 signalling, are to be administered directly to a brain or spinal cord.

10. The use according to any of claims 1 to 8, which further includes a P-glycoprotein inhibitor.

11. The use according to claim 10, wherein the P-glycoprotein inhibitor is elacridar.

12. The use according to claim 1, wherein the medicament further comprises a P-glycoprotein inhibitor, wherein the P-glycoprotein inhibitor is elacridar or quinidine.

13. The use according to claim 1, wherein the medicament further comprises one or more electrolytes present in endogenous CSF, wherein the one or more electrolytes is selected from sodium, potassium, calcium, magnesium, phosphorous, and chloride ions.

14. The use according to claim 13, wherein the medicament further comprises a solution comprising 150mM sodium ion, 3mM potassium ion, 1.4mM calcium ion, 0.8mM magnesium ion, 1.0mM phosphorous ion, and 155mM chloride ion.